Drug Index


Mechanism :

Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß. Based on modelling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL.

Indication :

  • Ph+ Chronic Myeloid Leukemia

Contraindications :

Myelosuppression including severe thrombocytopenia, neutropenia and anemia may occur; may manage by dose interruption, dose reduction, or discontinuation of therapy; hematopoietic growth factor has been used with resistant myelosuppression; monitor CBCs weekly for the first 2 months.

CNS and gastrointestinal hemorrhages, including fatalities have occurred; severe hemorrhage may require treatment interruption and transfusion.

Increased risk of developing pulmonary arterial hypertension (PAH); may be reversible on discontinuation; evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiation and during treatment; if PAH confirmed permanently discontinue therapy.

Hypokalemia, hypomagnesemia, congenital QT interval prolongation, hepatic impairment

Use with caution in patients who have or may develop prolongation of QT interval

Cardiac adverse reactions were reported in 5.8% of 258 patients including cardiomyopathy (1.6%), congestive heart failure, diastolic dysfunction, fatal myocardial infarction, and left ventricular dysfunction.

Risk of tumor lysis syndrome.

Risk of fluid retention and pleural/pericardial effusion.

Avoid pregnancy or impregnating women.

Avoid concomitant CYP3A4 inducers/inhibitors.

Dosing :

Not preferred in children <10 kg.
10-20 kg:
40 mg orally once everyday.
20-30 kg:
60 mg orally once everyday.
30-45 kg:
70 mg orally once everyday.
>45 kg:
100 mg orally once everyday.

Adverse Effect :

Fluid retention, diarrhea, headache, hemorrhage, fatigue, pyrexia, skin rash, infection, nausea, dyspnea, cough, pain, abdominal pain, vomiting, anorexia, arthralgia, asthenia, constipation, dizziness, musculoskeletal pain, weight loss, chest pain, neuropathy, myalgia, abdominal distention, arrhythmia, chills, pruritus, weight gain, anemia, febrile neutropenia, thrombocytopenia, mucosal inflammation.

Interaction :

CYP3A4 Inhibitors: Increase plasma concentrations and inducers decrease plasma concentrations.
Proton-pump inhibitor: Absorption decreased by PPI.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function. Use with caution

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnlikely to be dialysed. Dose as in normal renal function

Hepatic Dose :

No dosage adjustments are recommended. Use with caution.
02/18/2024 17:22:42 Dasatinib
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0